Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Impact of Insurance Status on Cost, Treatment, and Visual Outcomes in Patients with Diabetic Retinopathy
Author Affiliations & Notes
  • Michael Herron
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Martina Lange-Fernandez
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Lingchen Wang
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Hardeep Dhindsa
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Footnotes
    Commercial Relationships   Michael Herron None; Martina Lange-Fernandez None; Lingchen Wang None; Hardeep Dhindsa None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1818. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Herron, Martina Lange-Fernandez, Lingchen Wang, Hardeep Dhindsa; Impact of Insurance Status on Cost, Treatment, and Visual Outcomes in Patients with Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1818.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The factors contributing to the widespread prevalence of diabetic retinopathy in the United States are multifaceted. This study investigates one of many potential health disparities in eye care in an effort to elucidate the impact of social determinants of health on access to eye care. Specifically, this study investigates the impact of insurance status on visual outcomes, financial burden to patients, and qualitatively analyzes treatment interventions among insured versus uninsured patients with diabetic retinopathy.

Methods : This retrospective case-control study included 28 patients with diabetic retinopathy and 28 age-matched healthy controls. Parameters investigated included changes in best corrected visual acuity (BCVA), number and type of interventions received, overall charges to patients and insurance carriers.

Results : Differences were not found in treatment (p=0.980), charges (p=0.0873), or visual outcomes (p=0.189) between the groups, however, uninsured patients paid $286.13 more per visit on average compared to insured patients. Despite similar care and visual outcomes, uninsured patients have a much larger financial burden and were more commonly lost to follow up (p=0.013) than insured patients.

Conclusions : Compared with insured patients, uninsured patients pay significantly more for the same quality of care and comparable visual outcomes.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×